We are actively participating in the following trials:
BRAVO—MS-LAQ-302E, Phase III Open-Label Extension Study.
Evaluating Long-Term Safety, Tolerability and Effect on Disease Course of Daily Oral LAQUINIMOD 0.6 MG. TEVA PHARMACEUTICAL INDUSTRIES.
TYGRIS—TYSABRI Global Observational Program in Safety. BIOGEN IDEC
STRATEFY—2-JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with TYSABRI. BIOGEN IDEC
STRIVE—Observational, Open-Label, Single Arm Study of TYSABRI in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients. BIOGEN IDEC
RESPOND—Observational, Open-Label, 12- Month Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral TECFIDERA after Suboptimal response to GLATIRAMER ACETATE. BIOGEN IDEC
ESTEEM—Observational Study to collect information on safety and to document the drug utilization of TECFIDERA when used in routine medical practice for the treatment of Multiple Sclerosis. BIOGEN IDEC
STRATEGY—Observational Study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from TYSABRI to TECFIDERA. BIOGEN IDEC
ECU-NMO-301—Double-blind, Placebo-Controlled, Multi-Center Trial to evaluate the safety and efficacy of ECULIZUMAB in patients with relapsing Neuromyelitis Optica (NMO).
Learn more at ClinicalTrials.gov